Overall survival and intermediate outcomes among Scandinavian non‑small cell lung cancer patients: the SCAN‑LEAF study

S Ekman, JB Sørensen, J Rockberg, M Sandelin, M Daumont, P Sobocki, P Klint, H-Y Huang, J Svärd, O Chirita, L Jørgensen, M Planck

J Thorac Oncol. 2017;12(1 Suppl):S691.
https://doi.org/10.1016/j.jtho.2016.11.905

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Sweden, Denmark & Norway
I-O Data: No
Tx Patterns: No
Survival Data: Yes (OS)
HCRU: No

Non-small cell lung cancer (NSCLC) treatment and survival in Scandinavia: the SCAN-LEAF study

S Ekman, M Planck, OT Brustugun, J Rockberg, A Juarez-Garcia, M Manley Daumont, H Huang, M Pereira, J Svärd, M Rosenlund, O Chirita, L Jørgensen, M Sandelin, JB Sørensen

J Thorac Oncol. 2017;12(11 Suppl 2):S1881-S1882.
https://doi.org/10.1016/j.jtho.2017.09.632

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Sweden, Denmark & Norway
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Non‐small cell lung cancer (NSCLC) patient characteristics and clinical care insights in Sweden: the SCAN‑LEAF study

M Sandelin, M Planck, JB Sørensen, OT Brustugun, J Rockberg, A Juarez-Garcia, D Layton, M Manley Daumont, H Huang, M Pereira, J Svärd, M Rosenlund, O Chirita, L Jørgensen, S Ekman

J Thorac Oncol. 2017;12 (11 Suppl 2): S1990.
https://doi.org/10.1016/j.jtho.2017.09.906

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: Yes
Survival Data: No
HCRU: No

I-O Optimise: developing a unique multinational real‑world evidence‑based research platform in oncology

I Durand-Zaleski, M Manley-Daumont, P Baas, C Chaib, D Chao, C Chouaid, S Ekman, T d’Estrubé, F Griesinger, A Juarez-Garcia, M Khovratovich, D Layton, A McNamara, JC O’Donnell, JR Penrod, M Pereira, H Toft Sørensen

Value Health. 2017;20(9):A742-A743.
https://doi.org/10.1016/j.jval.2017.08.2055

View: poster

View: publication summary

Indication: Thoracic malignancies
Stage: N/A
Data Source: N/A
Country: N/A
I-O Data: No
Tx Patterns: No
Survival Data: No
HCRU: No

Clinical characteristics and overall survival of patients diagnosed with cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical a retrospective analysis of a UK hospital database

M Snee, S Cheeseman, M Thompson, P Godden, W Sopwith, C Chaib, A Juarez-Garcia, L Lacoin, JR Penrod, G Hall

Lung Cancer. 2018;115(Suppl 1):S38.
https://doi.org/10.1016/S0169-5002(18)30118-1

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Clinical characteristics and overall survival of patients diagnosed with non-small cell lung cancer (NSCLC) between 2006 and 2017 in routine clinical practice: a retrospective analysis of a UK hospital database

M Snee, S Cheeseman, M Thompson, P Godden, W Sopwith, C Chaib, A Juarez-Garcia, L Lacoin, JR Penrod, G Hall

Oncol Res Treat. 2018;41(Suppl 1):1-221.
https://doi.org/10.1159/000487109

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment patterns in patients with stage IIIB–IV NSCLC in clinical practice: retrospective analysis of a UK trust database

M Snee, S Cheeseman, M Thompson, M Riaz, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, J O’Donnell, G Hall

J Thorac Oncol. 2018;13(10 Suppl):S700.
https://doi.org/10.1016/j.jtho.2018.08.1145

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Initial treatment in patients (pts) diagnosed with non-small cell lung cancer (NSCLC) in Denmark from 2005‑2015: the SCAN-LEAF study

JB Sørensen, S Ekman, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, M Daumont, HC Jacobs, L Lacoin, OT Brustugun, M Planck

Ann Oncol. 2018;29(Suppl 8):viii493-viii547.
https://doi.org/10.1093/annonc/mdy292.104

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic (1L)
Data Source: SCAN-LEAF
Country: Denmark
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment patterns in patients (pts) with stage IIIB–IV non-small cell lung cancer (NSCLC) in Sweden: the SCAN‑LEAF study

S Ekman, M Planck, JB Sørensen, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, M Daumont, HC Jacobs, L Lacoin, OT Brustugun

Ann Oncol. 2018;29(Suppl 8):viii493-viii547.
https://doi.org/10.1093/annonc/mdy292.105

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Healthcare resource utilisation (HCRU) among patients with non-small cell lung cancer (NSCLC) in Sweden: the SCAN‑LEAF study

M Manley-Daumont, S Ekman, M Planck, OT Brustugun, P Horvat, D Layton, J Kim, M Rosenlund, A Juarez-Garcia, HC Jacobs, L Lacoin, JB Sørensen

Value Health. 2018;21(Suppl 3):PS58.
https://doi.org/10.1016/j.jval.2018.09.340

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: Yes
Survival Data: No
HCRU: Yes

Treatment patterns in patients with stage IIIB–IV NSCLC in clinical practice: retrospective analysis of a UK trust database

M Snee, S Cheeseman, M Thompson, M Riaz, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, J O’Donnell, G Hall

Thorax. 2018;73(Suppl 4):A145-A146.
https://thorax.bmj.com/content/73/Suppl_4/A145.2

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: an IPO‑PORTO database analysis from the I-O Optimise initiative

MAS Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O’Donnell, MJ Bento, FR Gonçalves

Ann Oncol. 2019 Apr 1;30(Suppl 2):ii16-ii17.
https://doi.org/10.1093/annonc/mdz070.003

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: a REAL-Oncology database analysis from the I-O Optimise initiative

M Snee, S Cheeseman, M Thompson, M Riaz, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, JC O’Donnell, G Hall

Ann Oncol. 2019 Apr 1;30(Suppl 2):ii14-ii15.
https://doi.org/10.1093/annonc/mdz070.002

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic (1L)
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Evolution of overall survival (OS) in patients (pts) with incident NSCLC in Denmark and Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative

JB Sørensen, S Ekman, OT Brustugun, P Horvat, D Patel, M Rosenlund, A Mette Kejs, A Juarez-Garcia, M Daumont, L Lacoin, JR Penrod, JC O’Donnell, M Planck

Ann Oncol. 2019 Apr 1;30(Suppl 2):ii16-ii17.
https://doi.org/10.1093/annonc/mdz070.004

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Denmark & Sweden
I-O Data: No
Tx Patterns: No
Survival Data: Yes (OS)
HCRU: No

Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: a SCAN-LEAF study analysis from the I-O Optimise initiative

S Ekman, JB Sørensen, OT Brustugun, P Horvat, D Patel, M Rosenlund, A Mette Kejs, A Juarez-Garcia, M Daumont, L Lacoin, JR Penrod, JC O'Donnell, M Planck

Ann Oncol. 2019 Apr 1;30(Suppl 2):ii17.
https://doi.org/10.1093/annonc/mdz070.005

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic (1L)
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Swedish national registries versus electronic medical records: comparing the completeness of systemic therapy data using data from the SCAN-LEAF study

P Horvat, A Mette-Kejs, Q Ann, V Lascano, B Bray, D Patel, S Ekman, L Lacoin, A Juarez-Garcia, J Kim

Pharmacoepidemiol Drug Saf. 2019 Aug 20;28(Suppl 2):424.
https://onlinelibrary.wiley.com/doi/10.1002/pds.4864

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: Yes
Survival Data: No
HCRU: No

Small cell lung cancer (SCLC) treatment and survival in Portugal: an IPO-PORTO analysis from the I-O Optimise initiative

M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, C Chaib, L Lacoin, A Juarez-Garcia, M Daumont, J Penrod, J O'Donnell, M Bento, F Rocha-Goncalves

J Thorac Oncol. 2019 Oct;14(10 Suppl):S820-S821.
https://doi.org/10.1016/j.jtho.2019.08.1764

View: poster

View: publication summary

Indication: SCLC
Stage: Limited & extensive (1L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Small cell lung cancer (SCLC) treatment and survival in the UK: a REAL-Oncology analysis from the I-O Optimise initiative

M Snee, S Cheeseman, M Thompson, R Bowman, L Lacoin, W Sopwith, C Chaib, A Juarez-Garcia, M Daumont, J Penrod, J O'Donnell, G Hall

J Thorac Oncol. 2019 Oct;14(10 Suppl):S812.
https://doi.org/10.1016/j.jtho.2019.08.1746

View: poster

View: publication summary

Indication: SCLC
Stage: Extensive (1L & 2L)
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Impact of second-line (2L) immune checkpoint inhibitors (ICIs) on the treatment (Tx) of advanced non-small cell lung cancer (NSCLC) in a UK centre: a REAL-Oncology analysis from the I-O Optimise initiative

M Snee, S Cheeseman, M Thompson, R Bowman, L Lacoin, W Sopwith, C Chaib, M Daumont, JR Penrod, JC O’Donnell, G Hall

Ann Oncol. 2019 Oct;30(Suppl 5):v616.
https://doi.org/10.1093/annonc/mdz260.023

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (2L)
Data Source: REAL-Oncology
Country: UK
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: an IPO‑PORTO database analysis from the I-O Optimise initiative

M Soares, L Antunes, P Redondo, M Borges, D Patel, F Grimson, C Chaib, JC O’Donnell, MJ Bento, FR Gonçalves

Not published (no citation)

View: poster 1 poster 2

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment patterns and outcomes in malignant pleural mesothelioma (MPM) in England: a nationwide CAS registry analysis from the I-O Optimise initiative

P Baas, M Daumont, L Lacoin, JR Penrod, R Carroll, N Tanna, S Venkatesan, H Ubhi, A Calleja, M Snee

Ann Oncol. 2020 Sep 1;31(Suppl 4):S1081-S1082.
https://doi.org/10.1016/j.annonc.2020.08.1452

View: poster

View: publication summary

Indication: MPM
Stage: Resectable & unresectable (1L & 2L)
Data Source: CAS
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Second-line immunotherapy treatment patterns in non-small cell lung cancer in Portugal: an I-O Optimise cohort study

M Soares, L Antunes, J Oliveira-Gomes, G Paupério, J Cardia, P Redondo, M Borges, C Chaib, L Lacoin, F Grimson, E Ralphs, R Munro, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, F Rocha Gonçalves

J Thorac Oncol. 2021 Mar 1;16(3 Suppl):S309-S310.
https://doi.org/10.1016/j.jtho.2021.01.470

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (2L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Real-world experience with nivolumab in patients with advanced non-small cell lung cancer at Frankfurt University Hospital

S Shaid, J Stratmann, A Wolf, N Niklas, A Calleja, R Munro, D Waldenberger, R Carroll, M Daumont, J Penrod, L Lacoin, G Rohde

J Thorac Oncol. 2021 Oct 1;16(10 Suppl):S1003-S1004
https://doi.org/10.1016/j.jtho.2021.08.316

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L+)
Data Source: Frankfurt
Country: Germany
I-O Data: Yes (nivolumab)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Trends in treatment patterns and survival in advanced NSCLC patients treated at Frankfurt University Hospital in 2012–2018

A Wolf, J Stratmann, S Shaid, N Niklas, A Calleja, R Munro, D Waldenberger, R Carroll, M Daumont, J Penrod, L Lacoin, G Rohde

J Thorac Oncol. 2021 Oct 1;16(10 Suppl):S1002-S1003.
https://doi.org/10.1016/j.jtho.2021.08.315

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L+)
Data Source: Frankfurt
Country: Germany
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Canadian real-world experience with nivolumab in patients with advanced non-small cell lung cancer previously treated with systemic anticancer therapy

R Carroll, M Bortolini, A Calleja, R Munro, S Kong, MJ Daumont, JR Penrod, L Lacoin, WY Cheung

Value Health. 2022;25(1 Suppl):S23.
https://doi.org/10.1016/j.jval.2021.11.103

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L+)
Data Source: O2
Country: Canada
I-O Data: Yes (nivolumab)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Impact of immune checkpoint inhibitors (ICIs) on the management of advanced non-small cell lung cancer (NSCLC) in real-world practice at Karolinska University Hospital, Stockholm between 2012 and 2018

S Ekman, OT Brustugun, JB Sørensen, AM Kejs, Q Ann, M Bortolini, A Calleja, L Rosengren, P Huetson, MJ Daumont, JR Penrod, HC Jacobs, L Lacoin, H Koyi

Value Health. 2022;25(1 Suppl):S132-S133.
https://doi.org/10.1016/j.jval.2021.11.635

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L+)
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: No
HCRU: No

Treatment patterns in patients with advanced non-small cell lung cancer (aNSCLC) after discontinuing an immune checkpoint inhibitor (ICI) therapy in second-line or later in Germany and France

F Griesinger, M Pérol, I Durand-Zaleski, L Bosquet, S Zacharias, A Calleja, S Patel, D Waldenberger, D Reynaud, R Carroll, MJ Daumont, JR Penrod, L Lacoin, C Chouaid

Ann Oncol. 2021 Dec 1;32(Suppl 7):S1422-S1423.
https://doi.org/10.1016/j.annonc.2021.10.127

View: poster

View: publication summary

Indication: NSCLC
Stage: Metastatic (1L & 2L+)
Data Source: CRISP & ESME
Country: Germany & France
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: No
HCRU: No

I-O Optimise: a novel multinational real-world research platform in thoracic malignancies

S Ekman, F Griesinger, P Baas, D Chao, C Chouaid, JC O’Donnell, JR Penrod, M Daumont, L Lacoin, A McKenney, M Khovratovich, REJ Munro, I Durand-Zaleski, S Paaske Johnsen

Future Oncol. 2019;15(14):1551-1563. doi: 10.2217/fon-2019-0025.
https://pubmed.ncbi.nlm.nih.gov/30852916/

Indication: Thoracic malignancies
Stage: N/A
Data Source: N/A
Country: N/A
I-O Data: No
Tx Patterns: No
Survival Data: No
HCRU: No

Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O’Donnell, MJ Bento, F Rocha Gonçalves

BMC Pulm Med. 2020;20(1):240. doi: 10.1186/s12890-020-01270-z
https://pubmed.ncbi.nlm.nih.gov/32912174/

Indication: NSCLC
Stage: Metastatic (1L & 2L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: No
Survival Data: Yes (OS)
HCRU: No

Small cell lung cancer treatment and survival in Portugal: a retrospective analysis from the I-O Optimise initiative

M Soares, L Antunes, P Redondo, M Borges, F Grimson, R Hermans, C Chaib, L Lacoin, A Juarez-Garcia, MJ Daumont, JR Penrod, MJ Bento, FR Gonçalves

Eur J Cancer Care (Engl). 2021;30(6):e13496. doi: 10.1111/ecc.13496
https://pubmed.ncbi.nlm.nih.gov/34288191/

Indication: SCLC
Stage: Limited & extensive (1L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

M Soares, L Antunes, P Redondo, M Borges, R Hermans, D Patel, F Grimson, R Munro, C Chaib, L Lacoin, M Daumont, JR Penrod, JC O'Donnell, MJ Bento, FR Gonçalves

Lung Cancer Manag. 2021 Feb 19;10(2):LMT46. doi: 10.2217/lmt-2020-0028
https://pubmed.ncbi.nlm.nih.gov/34084212/

Indication: NSCLC
Stage: Non-metastatic (1L)
Data Source: IPO-Porto
Country: Portugal
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non‑small cell lung cancer: a real‑world retrospective observational cohort study from the I‑O optimise initiative

M Snee, S Cheeseman, M Thompson, M Riaz, W Sopwith, L Lacoin, C Chaib, MJ Daumont, JR Penrod, JC O'Donnell, G Hall

BMJ Open. 2021 May 3;11(5):e043442. doi: 10.1136/bmjopen-2020-043442
https://pubmed.ncbi.nlm.nih.gov/33941627/

Indication: NSCLC
Stage: Metastatic
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Epidemiology and survival outcomes for patients with NSCLC in Scandinavia in the preimmunotherapy era: a SCAN‑LEAF retrospective analysis from the I‑O Optimise initiative

S Ekman, P Horvat, M Rosenlund, AM Kejs, D Patel, A Juarez-Garcia, L Lacoin, MJ Daumont, JR Penrod, OT Brustugun, JB Sørensen

JTO Clin Res Rep. 2021;2(5):100165. doi: 10.1016/j.jtocrr.2021.100165
https://pubmed.ncbi.nlm.nih.gov/34590017/

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Sweden
I-O Data: No
Tx Patterns: No
Survival Data: Yes (OS)
HCRU: No

Treatment patterns and survival outcomes for patients with non-small cell lung cancer in the UK in the preimmunology era: a REAL-Oncology database analysis from the I-O Optimise initiative

M Snee, S Cheeseman, M Thompson, M Riaz, W Sopwith, L Lacoin, C Chaib, MJ Daumont, JR Penrod, G Hall

BMJ Open. 2021 Sep 15;11(9):e046396. doi: 10.1136/bmjopen-2020-046396
https://pubmed.ncbi.nlm.nih.gov/34526333/

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: REAL-Oncology
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: a nationwide CAS registry analysis from the I-O Optimise initiative

P Baas, MJ Daumont, L Lacoin, JR Penrod, R Carroll, S Venkatesan, H Ubhi, A Calleja, M Snee

Lung Cancer. 2021 Dec;162:185-193. doi: 10.1016/j.lungcan.2021.11.001
https://pubmed.ncbi.nlm.nih.gov/34823894/

Indication: MPM
Stage: Resectable & unresectable (1L & 2L)
Data Source: CAS
Country: UK
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005–2015): SCAN-LEAF study

JB Sørensen, P Horvat, M Rosenlund, AM Kejs, D Patel, A Juarez-Garcia, L Lacoin, MJ Daumont, JR Penrod, JC O'Donnell, OT Brustugun, S Ekman

Future Oncol. 2022 Jan;18(2):205-214. doi: 10.2217/fon-2021-0746
https://pubmed.ncbi.nlm.nih.gov/34784783/

Indication: NSCLC
Stage: Metastatic & non-metastatic
Data Source: SCAN-LEAF
Country: Denmark
I-O Data: No
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis

R Carroll, M Bortolini, A Calleja, R Munro, S Kong, MJ Daumont, JR Penrod, K Lakhdari, L Lacoin, WY Cheung

BMC Cancer. 2022 Mar 10;22(1):255. doi: 10.1186/s12885-022-09342-5
https://bmccancer.biomedcentral.com/articles/
10.1186/s12885-022-09342-5

Indication: NSCLC
Stage: Metastatic (IL & 2L+)
Data Source: O2
Country: Canada
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

F Griesinger, M Pérol, N Girard, I Durand-Zaleski, S Zacharias, L Bosquet, M Jänicke, X Quantin, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, MJ Daumont, JR Penrod, R Carroll, D Waldenberger, D Reynaud, M Thomas, C Chouaid

Lung Cancer. 2022 Oct;172:65-74. doi: 10.1016/j.lungcan.2022.08.001
https://www.lungcancerjournal.info/article/S0169-5002(22)00577-3/fulltext

Indication: NSCLC
Stage: Metastatic (1L)
Data Source: CRISP & ESME
Country: Germany & France
I-O Data: Yes (all I-O)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No

Effectiveness of nivolumab in second-Line and later in patients with advanced non-small cell lung cancer in real-life practice in France and Germany: analysis of the ESME-AMLC and CRISP cohorts

C Chouaid, M Thomas, D Debieuvre, I Durand-Zaleski, S Zacharias, L Bosquet, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, MJ Daumont, JR Penrod, R Carroll, D Waldenberger, F-E Cotté, C Audigier-Valette, F Griesinger

Cancers. 2022;14(24): 6148. doi.org/10.3390/cancers14246148
https://www.mdpi.com/2072-6694/14/24/6148

Indication: NSCLC
Stage: Metastatic (2L+)
Data Source: CRISP & ESME
Country: Germany & France
I-O Data: Yes (nivo)
Tx Patterns: No
Survival Data: Yes (OS)
HCRU: No

Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018

A Wolf, JA Stratmann, S Shaid, N Niklas, A Calleja, H Ubhi, R Munro, D Waldenberger, R Carroll, MJ Daumont, JR Penrod, L Lacoin, G Rohde

BMC Pulm Med. 2023;23(1):16. doi.org/10.1186/s12890-022-02288-1
https://bmcpulmmed.biomedcentral.com/articles/
10.1186/s12890-022-02288-1

Indication: NSCLC
Stage: Metastatic (1L+)
Data Source: Frankfurt
Country: Germany
I-O Data: Yes (all)
Tx Patterns: Yes
Survival Data: Yes (OS)
HCRU: No